Literature DB >> 25634646

Factors affecting recall of different types of personal genetic information about Alzheimer's disease risk: the REVEAL study.

Andria G Besser1, Saskia C Sanderson, J Scott Roberts, Clara A Chen, Kurt D Christensen, Denise M Lautenbach, L Adrienne Cupples, Robert C Green.   

Abstract

METHODS: Data were obtained through a multisite clinical trial in which different types of genetic risk-related information were disclosed to individuals (n = 246) seeking a risk assessment for Alzheimer's disease.
RESULTS: Six weeks after disclosure, 83% of participants correctly recalled the number of risk-increasing APOE alleles they possessed, and 74% correctly recalled their APOE genotype. While 84% of participants recalled their lifetime risk estimate to within 5 percentage points, only 51% correctly recalled their lifetime risk estimate exactly. Correct recall of the number of APOE risk-increasing alleles was independently associated with higher education (p < 0.001), greater numeracy (p < 0.05) and stronger family history of Alzheimer's disease (p < 0.05). Before adjustments for confounding, correct recall of APOE genotype was also associated with higher education, greater numeracy and stronger family history of Alzheimer's disease, as well as with higher comfort with numbers and European American ethnicity (all p < 0.05). Correct recall of the lifetime risk estimate was independently associated only with younger age (p < 0.05).
CONCLUSIONS: Recall of genotype-specific information is high, but recall of exact risk estimates is lower. Incorrect recall of numeric risk may lead to distortions in understanding risk. Further research is needed to determine how best to communicate different types of genetic risk information to patients, particularly to those with lower educational levels and lower numeracy. Health-care professionals should be aware that each type of genetic risk information may be differentially interpreted and retained by patients and that some patient subgroups may have more problems with recall than others.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25634646      PMCID: PMC4470386          DOI: 10.1159/000368888

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN: 1662-4246            Impact factor:   2.000


  23 in total

1.  An inventory for measuring clinical anxiety: psychometric properties.

Authors:  A T Beck; N Epstein; G Brown; R A Steer
Journal:  J Consult Clin Psychol       Date:  1988-12

2.  Communicating consequences of risky behaviors: Life expectancy versus risk of disease.

Authors:  Mirta Galesic; Rocio Garcia-Retamero
Journal:  Patient Educ Couns       Date:  2010-03-12

3.  Patients' resistance to risk information in genetic counseling for BRCA1/2.

Authors:  Andrea D Gurmankin; Susan Domchek; Jill Stopfer; Christina Fels; Katrina Armstrong
Journal:  Arch Intern Med       Date:  2005-03-14

4.  Family history of breast cancer: what do women understand and recall about their genetic risk?

Authors:  M Watson; V Duvivier; M Wade Walsh; S Ashley; J Davidson; M Papaikonomou; V Murday; N Sacks; R Eeles
Journal:  J Med Genet       Date:  1998-09       Impact factor: 6.318

Review 5.  Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.

Authors:  J S Roberts; K D Christensen; R C Green
Journal:  Clin Genet       Date:  2011-07-18       Impact factor: 4.438

6.  The use of videotaped information in cancer genetic counselling: a randomized evaluation study.

Authors:  A Cull; H Miller; T Porterfield; J Mackay; E D Anderson; C M Steel; R A Elton
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 7.  Clinical implications of numeracy: theory and practice.

Authors:  Wendy Nelson; Valerie F Reyna; Angela Fagerlin; Isaac Lipkus; Ellen Peters
Journal:  Ann Behav Med       Date:  2008-08-02

8.  Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study.

Authors:  Susan LaRusse Eckert; Heather Katzen; J Scott Roberts; Melissa Barber; Lisa D Ravdin; Norman R Relkin; Peter J Whitehouse; Robert C Green
Journal:  Genet Med       Date:  2006-12       Impact factor: 8.822

9.  Exome sequencing improves genetic diagnosis of structural fetal abnormalities revealed by ultrasound.

Authors:  Keren J Carss; Sarah C Hillman; Vijaya Parthiban; Dominic J McMullan; Eamonn R Maher; Mark D Kilby; Matthew E Hurles
Journal:  Hum Mol Genet       Date:  2014-01-29       Impact factor: 6.150

10.  The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine.

Authors:  Jason L Vassy; Denise M Lautenbach; Heather M McLaughlin; Sek Won Kong; Kurt D Christensen; Joel Krier; Isaac S Kohane; Lindsay Z Feuerman; Jennifer Blumenthal-Barby; J Scott Roberts; Lisa Soleymani Lehmann; Carolyn Y Ho; Peter A Ubel; Calum A MacRae; Christine E Seidman; Michael F Murray; Amy L McGuire; Heidi L Rehm; Robert C Green
Journal:  Trials       Date:  2014-03-20       Impact factor: 2.279

View more
  3 in total

1.  Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.

Authors:  Victoria S Marshe; Ilona Gorbovskaya; Sarah Kanji; Maxine Kish; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2018-10-31       Impact factor: 3.575

2.  A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone.

Authors:  Kurt D Christensen; Wendy R Uhlmann; J Scott Roberts; Erin Linnenbringer; Peter J Whitehouse; Charmaine D M Royal; Thomas O Obisesan; L Adrienne Cupples; Melissa B Butson; Grace-Ann Fasaye; Susan Hiraki; Clara A Chen; Uwe Siebert; Robert Cook-Deegan; Robert C Green
Journal:  Genet Med       Date:  2017-07-20       Impact factor: 8.822

3.  Knowledge assessment and psychological impact of genetic counseling in people at risk for familial FTD.

Authors:  Bonnie Wong; Diane Lucente; Samantha Krivensky; Erin Krahn; Jason Karlawish; Bradford C Dickerson
Journal:  Alzheimers Dement (Amst)       Date:  2021-07-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.